# A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

> **NCT02588131** · PHASE2 · UNKNOWN · sponsor: **Italian Network for Tumor Biotherapy Foundation** · enrollment: 40 (estimated)

## Conditions studied

- Pleural Mesothelioma
- Peritoneal Mesothelioma

## Interventions

- **DRUG:** tremelimumab plus MEDI4736

## Key facts

- **NCT ID:** NCT02588131
- **Lead sponsor:** Italian Network for Tumor Biotherapy Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2016-06
- **Final completion:** 2018-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2015-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588131, "A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02588131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*